Functional service provisions can provide sponsors and CROs with a way to efficiently manage clinical trial outsourcing methods.
What works when and for whom in the era of comparative effectiveness research.
What works when and for whom in the era of comparative effectiveness research.
The Pediatric Working Group of the European CRO Federation conducted a follow-up survey on the status of pediatric clinical trials in Europe.
How molecular profiling is impacting today's cancer medicine.
The eClinical Forum Risk Based Monitoring Taskforce offers some best practices for ensuring clinical data quality.
In a recent piece published in the New England Journal of Medicine, oncologist Dr. Ethan Basch talks about his perspective that patient-reported outcomes (PROs) are not widely used in the development process for cancer drugs because they are not often measured in clinical trials.
Life can change in an instant, but there is one thing that always abides: hope.
The eClinical Forum Risk Based Monitoring Taskforce offers some best practices for ensuring clinical data quality.
Conversion from paper to ePRO for an instrument designed to assess diabetes' impact on quality of life.
An analysis of warning letters and the findings reported from 1996 to 2010.
A first vaccine against this coronavirus could still take some time to develop, but mRNA vaccine platforms could offer an early breakthrough.
eGSP-driven approach focuses on overcoming operational challenges through data integration.
How to satisfy regulatory concerns about EDC data integrity and site controls over its source records.
eGSP-driven approach focuses on overcoming operational challenges through data integration.
A quantitative approach to enhancing risk assessment and mitigation in drug development.
The eClinical Forum Risk Based Monitoring Taskforce offers some best practices for ensuring clinical data quality.
With a month left to join one of the 24 ERNs, Peter O'Donnell writes that this initiative is a welcomed demonstration of how cooperation can function in the common interest.
Though the global pandemic that has affected millions, the industry has shown resilience and demonstrated a shared commitment to improving patient care.
The data, not the plan, provide the direction.
Arthur L. Caplan, Ph.D., chair of the University of Pennsylvania's Department of Medical Ethics, expressed his frank views about issues that are ailing the drug industry today during his DIA Keynote Address in mid-June.
As the pharmaceutical industry continues to face increasing cost of drug development, sample banking for future clinical research provides the pharmaceutical industry with new opportunities to obtain biological sample collections that will allow it to investigate safety and efficacy in future clinical research and answer regulatory authority questions related to safety and efficacy at the time of registration.
Rising costs and evolving compound developments underline need for understanding at every step.
The Pediatric Working Group of the European CRO Federation conducted a follow-up survey on the status of pediatric clinical trials in Europe.
What works when and for whom in the era of comparative effectiveness research.
The eClinical Forum Risk Based Monitoring Taskforce offers some best practices for ensuring clinical data quality.